BioSyent Releases Financial Results for Q2 and H1 2025

Executive Summary

• BioSyent Inc. released its financial results for the three and six months ended June 30, 2025, reporting significant growth in sales and profitability across all segments.
• Total company sales increased by 14% year-over-year in Q2 2025 and 27% in H1 2025, driven by strong performance in both Canadian and International Pharma divisions.
• Net Income After Taxes (NIAT) rose 28% in Q2 and 30% in H1, with EBITDA growing 35% and 40% respectively, while the company also announced a new quarterly dividend declaration.

Key Details

• Q2 2025 Financials:
  • Total Company Sales: $10,179,296 (+14% vs Q2 2024)
  • Canadian Pharma Sales: $9,327,224 (+9% vs Q2 2024)
  • International Pharma Sales: $445,614 (+183% vs Q2 2024)
  • EBITDA: $2,760,149 (+35% vs Q2 2024)
  • Net Income After Taxes (NIAT): $2,018,171 (+28% vs Q2 2024)
  • Fully Diluted EPS: $0.18 (+31% vs Q2 2024)
• H1 2025 Financials:
  • Total Company Sales: $21,158,256 (+27% vs H1 2024)
  • Canadian Pharma Sales: $18,486,876 (+15% vs H1 2024)
  • International Pharma Sales: $1,980,830 (+1,160% vs H1 2024)
  • EBITDA: $5,961,796 (+40% vs H1 2024)
  • Net Income After Taxes (NIAT): $4,338,104 (+30% vs H1 2024)
  • Fully Diluted EPS: $0.38 (+33% vs H1 2024)
• Trailing Twelve Months (TTM) Performance (as of June 30, 2025):
  • Total Company Sales: $39,510,951 (+17% vs TTM June 30, 2024)
  • EBITDA: $11,052,544 (+26% vs TTM June 30, 2024)
  • Net Income After Taxes (NIAT): $8,259,192 (+16% vs TTM June 30, 2024)
  • Fully Diluted EPS: $0.72 (+20% vs TTM June 30, 2024)
  • Return on Average Equity: 23% (vs 21% in prior TTM)
• Balance Sheet Highlights (as of June 30, 2025):
  • Cash, cash equivalents, and short-term investments: $20,364,392
  • Total Assets: $43,495,489
  • Total Equity: $37,600,753
• Corporate Actions:
  • Repurchased 19,500 common shares for cancellation under Normal Course Issuer Bid (NCIB) during H1 2025.
  • Paid quarterly cash dividends of $0.05 per share on March 14, 2025, and June 13, 2025.
  • Declared subsequent cash dividend of $0.05 per common share to be paid on September 15, 2025.
• Operational Updates:
  • Canadian Pharma sales growth attributed to FeraMAX® Pd and Tibella® (tibolone), despite economic uncertainty regarding tariffs.
  • International Tibella® business generated $1.3 million in incremental revenues year-to-date following the September 2024 acquisition of worldwide rights.
  • Net profit margin improved to 21% of sales in H1 2025 (up from 20% in the comparative period) due to a reduction in the operating expense ratio, despite tightened gross margins from product mix changes.

Notable Quotes

• “Each of our Canadian Pharma, International Pharma, and Legacy businesses continued to perform well during Q2 2025, delivering 14% sales growth and 28% net profit growth overall,” commented Mr. René Goehrum, President and CEO of BioSyent.
• “With momentum in all of our businesses as we enter the second half of 2025, I look forward to reporting on our continued progress. We remain committed to long-term value creation through portfolio diversification and profitable growth.”